What records are connected here?
- Evidence lanes
- 3
- Source years
- 18
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2,3Evidence: Large human trialsHeart and blood vessels
Nesiritide is a recombinant form of human B-type natriuretic peptide, a 32-amino-acid peptide, according to FDA’s substance registry. It was the active ingredient in Natrecor, which FDA approved in 2001.1,3 In ASCEND-HF, a randomized trial of 7,141 people hospitalized with acute heart failure, nesiritide did not significantly reduce death or rehospitalization or meet its goal for breathlessness, and it caused more low blood pressure.4 FDA withdrew Natrecor’s approval in 2020 after the company told FDA it was no longer marketed.2
| What it is | Recombinant human B-type (brain) natriuretic peptide of 32 amino acids, also recorded as BNP-32, according to FDA’s substance registry.1 |
|---|---|
| FDA status | Not FDA-approved. FDA withdrew approval of Natrecor, NDA 020920, as of June 15, 2020, after the applicant reported it was no longer marketed.2,3 |
| Human evidence | Large randomized trials, including ASCEND-HF in 7,141 people with acute heart failure, published in 2011.4 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Nesiritide is a recombinant form of human B-type natriuretic peptide of 32 amino acids. FDA’s substance registry also records it as BNP-32 and brain natriuretic peptide 32.1
It was the active ingredient of Natrecor, approved under NDA 020920 on August 10, 2001, according to Drugs@FDA.3
The sources reviewed here do not describe its mechanism. The ASCEND-HF investigators describe it as approved in the United States for early relief of breathlessness in acute heart failure.1,4
ASCEND-HF randomized 7,141 people hospitalized with acute heart failure to nesiritide or placebo on top of standard care. Moderate or marked improvement in breathlessness was slightly more common with nesiritide, but the difference did not reach the trial’s prespecified level of significance.4
Rehospitalization for heart failure or death within 30 days occurred in 9.4% given nesiritide and 10.1% given placebo, a difference that was not significant. Kidney function did not worsen more often, but low blood pressure was more common with nesiritide.4
The investigators concluded that nesiritide could not be recommended for routine use in the broad population of people with acute heart failure.4
Evidence-strength label: Large randomized human trials. How this label is assigned
Not now. FDA’s May 14, 2020 Federal Register notice states that approval of 16 applications, including Natrecor, NDA 020920, is withdrawn as of June 15, 2020, because the applicants reported that the products were no longer marketed and asked for withdrawal.2
Drugs@FDA lists Natrecor with an original approval date of August 10, 2001.3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list nesiritide.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Nesiritide is not among them.6,7
Whether any group of people with acute heart failure benefits clearly: ASCEND-HF found no significant effect on its main outcomes across the broad population it studied.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Nesiritide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Nesiritide are a bounded selection, not every registration or paper about Nesiritide. For the years before Nesiritide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Nesiritide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Nesiritide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA approval withdrawn in 2020 after the product left the market. A randomized trial of 7,141 people with acute heart failure found no significant effect on death or rehospitalization and more low blood pressure. Nesiritide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA approval withdrawn in 2020 after the product left the market. A randomized trial of 7,141 people with acute heart failure found no significant effect on death or rehospitalization and more low blood pressure. Nesiritide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 8, 2026
Nesiritide in acute decompensated heart failure: current status and future perspectives.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Nesiritide in acute decompensated heart failure: current status and future perspectives.↗Source date November 8, 2026Literature metadata · added November 16, 2026
Nesiritide: the clinical experience.↗Source date May 13, 2026Literature metadata · added November 16, 2026
Nesiritide following maze and mitral valve surgery.↗Source date April 28, 2025PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
25 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 23, 1998 to November 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18928481 in Journal of cardiac surgery as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.↗
Literature metadata
PubMed lists PMID 31948318 in The Journal of international medical research as Journal Article, Meta-Analysis, with publication-date metadata of 2020-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.↗
Literature metadata
PubMed lists PMID 17192168 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 17461695 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 15470300 in Congestive heart failure (Greenwich, Conn.) as Journal Article, Review, with publication-date metadata of 2004 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 15605677 in International journal of clinical practice as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 15102572 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 16509026 in Pharmacotherapy as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Federal Register · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
The New England Journal of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026